RachelElizabethSanbornMD

Full Member: Medical Director, Thoracic Oncology Program; Medical Director, Phase I Clinical Trials Program, Earle A. Chiles Research Institute, Providence Cancer Institute | Medical Oncology, Providence Portland Medical Center

Join to view full profile

Dr. Sanborn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sanborn's full profile

Already have an account?

Office
4805 Ne Glisan
Ste 11N-1
Portland, OR 97213
Phone+1 503-215-5696

Fax+1 503-215-5695

Summary

Dr. Sanborn is Medical Director of the Thoracic Oncology Program at Providence Cancer Institute, and Medical Director of the Phase I Clinical Trials Program at Earle A. Chiles Research Institute, a division of Providence. She is a Full Member of the Earle A. Chiles Research Institute at Providence Cancer Institute. She is board-certified in medical oncology and internal medicine, and serves as a member of the Institutional Review Board of Providence Portland Medical Center.

Dr. Sanborn completed her medical degree and hematology and medical oncology fellowship at Oregon Health & Science University. She attended the University of Illinois at Chicago for her residency in internal medicine.

Dr. Sanborn is a member of several professional organizations, including the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, the American Lung Association Medical Advisory Workgroup, the Southwest Oncology Group Thoracic Working Group, and the Hoosier Cancer Research Network Thoracic Clinical Trial Working Group.

Education & Training

Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2002 - 2005
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1999 - 2002
Oregon Health and Science University School of MedicineClass of 1999
Cornell CollegeBA, Biology, 1995

Certifications & Licensure

OR State Medical License 2005 - 2025
IL State Medical License 1999 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 2
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Start of enrollment: 2010 Oct 14
Completed
Phase 1
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. Start of enrollment: 2011 Jul 01
Active, not recruiting
Phase 2
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 1
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions Start of enrollment: 2012 Apr 27
Completed
Phase 1
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Chemoimmunotherapy and Radiation in Pancreatic Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Start of enrollment: 2013 Nov 01
Completed
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
α-TEA in Advanced Cancer Start of enrollment: 2014 Aug 04
Completed
Phase 1
Pilot Study of DRibble Vaccine for Prostate Cancer Patients Start of enrollment: 2014 Oct 24
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Start of enrollment: 2015 May 06
Active, not recruiting
Phase 3
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Start of enrollment: 2017 Feb 23
Terminated
Phase 1
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients Start of enrollment: 2019 Apr 03
Active, not recruiting
Phase 2
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Start of enrollment: 2019 Oct 09
Terminated
Phase 2
A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors Start of enrollment: 2019 Oct 18
Completed
Phase 1
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Start of enrollment: 2020 May 29
Terminated
Phase 1
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Start of enrollment: 2020 Jun 18
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator, Sponsor-Investigator
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Aug 17
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of SGN-EGFRd2 in Advanced Solid Tumors Start of enrollment: 2023 Nov 14
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1127 citations
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):...
Naiyer A. Rizvi, Julien Mazieres, David Planchard, Thomas E. Stinchcombe, Grace K. Dy
The Lancet. Oncology. 2015-03-01
302 citations
Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study
Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu
Journal of Clinical Oncology. 2021-08-02
7 citations
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Pr...
Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom
Journal of Clinical Oncology. 2024-10-20

Lectures

Targeted Onocology Cased-Based Peer Perspectives on Targeted Therapy and IO for Lung Cancer
Tacoma, WA (Virtual Meeting) - 8/2020
Case-Based Peer Perspectives in EGFR-Mutated NSCLC and in Small Cell Lung Cancer
Tacoma, WA (Virtual Meeting) - 6/2020
Maximizing the Benefits of Targeted Therapies
Chicago, IL (ASCO Virtual Meeting) - 5/2020
JNJ-372
Santa Monica, CA - 2/2020
IO + CDX1140
Santa Monica, CA - 2/2020
PF-06939999
Santa Monica, CA - 2/2020
Progress in Non-Small Cell Lung Cancer: Yes, Really
Portland, OR - 1/2020
Phase (Ph) I/II study of pembrolizumab (P) with gemcitabine (G) in patients (pts) with previously-treated advanced (Adv) non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019
Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (i...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

“All Patients Should Have Their Tumor Sequenced at Least Once”June 13th, 2022
TKI plus SBRT Tops TKI Alone for Oligometastatic EGFRm NSCLCJune 8th, 2020
Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130December 16th, 2019
Join now to see all